CTOs on the Move

Tari Labs

www.tari.com

 
Tari is a new open source, digital assets focused blockchain protocol that is being architected as a merge-mined sidechain with Monero. We chose to focus specifically on digital assets – things like tickets, loyalty points, in-game items, and crypto-native assets like CryptoKitties – because we see a huge opportunity to revolutionize the way these assets are owned, managed and transferred.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Skye Multimedia

Skye Multimedia is a Bridgewater, NJ-based company in the Software and Internet sector.

Rumble Network Discovery

Rumble Network Discovery leverages applied research to identify network assets quickly, easily, and comprehensively without credentials or tap port access.

MetaCommunications

MetaCommunications develops workflow and collaborative productivity solutions that automate marketing, brand management, creative design, packaging and prepress processes so organizations around the world can be more productive. With thousands of customer sites worldwide, we have the solid experience and range of solutions to quickly help your organization take its productivity to the next level through improved processes, workflows and communications. MetaCommunications produces its flagship product Workgroups DaVinci™, as either an on-premise installation or as a cloud-hosted solution. We also provide turnkey implementation, best practices consulting and training services.

DataRemote

Data Remote is the leading expert in wireless and cellular technology. They offer specialized M2M solutions to businesses in various industries all over the world.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.